JSON
Beser J, Galanis I, Enkirch T, Kühlmann Berenzon S, van Straten E, Duracz J, Rapp M, Zakikhany K, Mansjö M, Wigren Byström J, Forsell MNE, Groenheit R, Tegmark Wisell K, Bråve A
Sci Rep 12 (1) 10816 [2022-06-25; online 2022-06-25]
A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April-May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and among non-vaccinated 20.1% had detectable levels of antibodies. We tested for differences in seroprevalence between age groups and by sex and estimated seroprevalence among previously infected participants by time since reporting.
Category: Genomics & transcriptomics
PubMed 35752708
DOI 10.1038/s41598-022-15183-w
Crossref 10.1038/s41598-022-15183-w
pii: 10.1038/s41598-022-15183-w
pmc: PMC9233662